AWM
URGN icon

Avior Wealth Management’s UroGen Pharma URGN Stock Holding History

Avior Wealth Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4
Closed -$60 – 3666
2024
Q1 		$60 Buy
+4
New +$65 ﹤0.01% 3409

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Avior Wealth Management's URGN Position: Q2 2024 in Review

Avior Wealth Management sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 4 shares — an estimated $60 sold.

Avior Wealth Management first reported a position in URGN in Q1 2024 and held it in 1 quarter. The position peaked at $60 in Q1 2024. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

  • Avior Wealth Management reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 4 UroGen Pharma shares in Q2 2024, an estimated $60.
  • Avior Wealth Management first reported a position in UroGen Pharma in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's UroGen Pharma position peaked at $60 in Q1 2024.
  • 115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.